The home of the Audio Journal of Oncology
AUDIO JOURNAL OF ONCOLOGY—Pan-AKT Inhibitor Tumor Agnostic Targeting  was Safe and Effective in Phase One Study

AUDIO JOURNAL OF ONCOLOGY—Pan-AKT Inhibitor Tumor Agnostic Targeting  was Safe and Effective in Phase One Study

Play episode

Audio Journal of Oncology Podcast
Audio Journal of Oncology Podcast
AUDIO JOURNAL OF ONCOLOGY—Pan-AKT Inhibitor Tumor Agnostic Targeting  was Safe and Effective in Phase One Study
AUDIO JOURNAL OF ONCOLOGY—Pan-AKT Inhibitor Tumor Agnostic Targeting  was Safe and Effective in Phase One Study
/

Pan-AKT Inhibitor Tumor Agnostic Targeting  was Safe and Effective in Phase One Study

BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT inhibitor ipatasertib in a phase one study reported at the 2022 EORTC—NCI—AACR symposium on Molecular Targets and Cancer Therapeutics.

Nearly a quarter of the patients treated with the AKT blocker had their tumors shrink. These included patients with breast, endometrial cancer and salivary gland cancers. And tumors remained stable in just over half of the remaining patients.

AUDIO JOURNAL OF ONCOLOGY—Pan-AKT Inhibitor Tumor Agnostic Targeting  was Safe and Effective in Phase One Study
Commissioned by the Department of Medicine, Division of Hematology/Oncology

The first author at the Barcelona symposium, Kevin Kalinsky MD MS, Director of Breast Medical Oncology, Emory University at Winship Cancer Institute, Hematology and Medical Oncology, Atlanta, USA talks with Peter Goodwin.

More from this show

Sign up for AudioMedica.com news

* = required field
Speciality